Treatment of Fibromyalgia with Severe Sleep Disturbance

When fibromyalgia is accompanied by severe sleep disturbance, sleep disruption becomes a distinct and central clinical target. This population requires a treatment approach that specifically addresses impaired sleep alongside the broader fibromyalgia syndrome.

Clinical Scenario

This protocol addresses patients with fibromyalgia who present with severe sleep disturbance. Current evidence supports considering pharmacological therapy specifically for this sub-population, recognising that sleep impairment demands targeted intervention.

Treatment Approach

Pharmacological options — including certain tricyclic and neuromodulatory agents — are recommended for fibromyalgia with severe sleep disturbance. The structured regimen, encompassing all recommended agents, sequencing, and decision points, is available in the complete protocol.

Clinical Goal

The primary treatment target is meaningful improvement in sleep quality, assessed at 6–8 weeks.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2016-209724

Pharmacological therapies (all 'weak for') should be considered for those with severe pain (duloxetine, pregabalin, tramadol) or sleep disturbance (amitriptyline, cyclobenzaprine, pregabalin).
Nishishinya et al in their high-quality review concluded that 25 mg/day improved pain, sleep and fatigue at 6–8 weeks of treatment but not at 12 weeks while 50 mg/day did not demonstrate efficacy.
Häuser et al reported that patients receiving amitriptyline were more likely to achieve 30% pain reduction (risk ratio (RR) 1.60, 95% CI 1.15 to 2.24), equivalent to a 'number needed to treat' (NNT) of 3.54, 95% CI 2.74 to 5.01.
There was a moderate effect on sleep (standardised mean difference (SMD) −0.56, 95% CI −0.78, to −0.34) and small effect on fatigue (−0.44; −0.71 to −0.16).

View source ↗